04101nam 2200637Ia 450 991084134400332120230607214110.01-280-27111-697866102711150-470-66827-X0-470-85929-60-470-86079-0(CKB)111087027094322(EBL)152690(SSID)ssj0000206255(PQKBManifestationID)11174701(PQKBTitleCode)TC0000206255(PQKBWorkID)10226918(PQKB)10074680(MiAaPQ)EBC152690(OCoLC)85820041(EXLCZ)9911108702709432220021223d2002 uy 0engur|n|---|||||txtccrMucus hypersecretion in respiratory disease[electronic resource]Chichester, West Sussex, England ;Hoboken, NJ, USA Wiley20021 online resource (304 p.)Novartis Foundation symposium ;248"Editors, Derek J. Chadwick and Jamie A. Goode"--P. [v]."Symposium on Mucus Hypersecretion in Respiratory Disease, held at the Novartis Foundation, London, 26-28 February 2002"--P. [v].0-470-84478-7 Includes bibliographical references and indexes.MUCUS HYPERSECRETION IN RESPIRATORY DISEASE; Contents; Participants; Chair's introduction; Epidemiological studies in mucus hypersecretion; Discussion; Post-secretory fate of host defence components in mucus; Discussion; Mechanisms of submucosal gland morphogenesis in the airway; Discussion; Mucin-producing elements and inflammatory cells; Discussion; Respiratory tract mucins: structure and expression patterns; Discussion; Development and validation of a lectin-based assay for the quantitation of rat respiratory mucin; Discussion; Regulation of mucin secretion from in vitro cellular modelsDiscussionOscillations of pH inside the secretory granule control the gain of Ca(2+) release for signal transduction in goblet cells exocytosis; Discussion; A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction; Discussion; Mechanisms by which Gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR); Discussion; Non-allergic models of mucous cell metaplasia and mucus hypersecretion in rat nasal and pulmonary airways; DiscussionCytokine regulation of mucus production in a model of allergic asthmaDiscussion; The role of apoptotic regulators in metaplastic mucous cells; Discussion; Current and future therapies for airway mucus hypersecretion; Discussion; Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases; Discussion; Final general discussion; Index of contributors; Subject indexA number of chronic respiratory diseases including chronic bronchitis, asthma, cystic fibrosis and bronchiectasis are characterized by mucus hypersecretion. Following damage to the airway epithelium, a repair process of dedifferentiation, regenerative proliferation and redifferentiation takes place that is invariably accompanied by mucus hypersecretion as a key element in the host defence mechanism. In chronic respiratory diseases, however, excessive mucus production leads to a pathological state with increased risk of infection, hospitalization and morbidity. An understanding of the mechanismNovartis Foundation symposium ;248.Mucous membraneRespiratory organsDiseasesMucous membrane.Respiratory organsDiseases.616.2Chadwick Derek91632Goode Jamie283336Novartis Foundation.MiAaPQMiAaPQMiAaPQBOOK9910841344003321Mucus hypersecretion in respiratory disease4142337UNINA